Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Visceral Pain Market Growth Performance Trended Historically, And What Lies Ahead?
Over the past few years, there has been a robust growth in the market size of visceral pain. It is projected to expand from $13.84 billion in 2024 to $14.82 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 7.1%. The surge during the historic period is primarily due to an aging population, escalating prevalence of chronic diseases, advancements in medical investigations, enhancements in healthcare facilities, and an increase in awareness and diagnosis rates.
The market for visceral pain is anticipated to witness robust expansion in the forthcoming years. It is projected to escalate to$18.58 billion by 2029 with a compound annual growth rate (CAGR) of 5.8%. This growth during the prediction period can be ascribed to advancements in technology related to pain management, a burgeoning need for non-invasive treatment methods, emerging markets and available opportunities yet to be explored, strategies in personalised medicines, and incorporation of digital health solutions. Notable trends during this projection period incorporate a shift toward multi-faceted pain management, a rising focus on alternative therapies, the emergence of targeted treatments for specific types of pain, the increasing importance of telemedicine in managing pain, and the deployment of artificial intelligence in pain evaluation.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13950&type=smp
What Are the Major Market Drivers Behind the Rising Adoption of Visceral Pain Market?
The visceral pain market is anticipated to expand due to the increasing need for analgesics. These are medicines designed to help relieve pain by lessening or inhibiting the sensory perception of pain signals in the brain. They function in managing visceral pain by acting on the nervous system and modulating signals of pain originating from the body’s inner organs. For instance, in the New England Journal of Medicine, a weekly medical journal based in the UK, it was documented in April 2024 that by December 2023, over 53,600 clinicians had begun prescribing buprenorphine. This was a rise of 11,500 prescribers from December 2022. Consequently, the growing requirement for analgesics is propelling the expansion of the visceral pain market.
Which Key Market Segments Comprise the Visceral Pain Market and Drive Its Revenue Growth?
The visceral painmarket covered in this report is segmented –
1) By Drug Class: Calcium Channel Blockers; Nonsteroidal Anti-Inflammatory (NSAID); Other Drug Classes
2) By Indications: Interstitial Cystitis; Crohn’s; Irritable Bowel; Chronic Prostatitis; Other Indications
3) By End Users: Hospitals; Homecare; Specialty Clinics; Other End Users
Subsegments:
1) By Calcium Channel Blockers: Dihydropyridines; Non-Dihydropyridines
2) By Nonsteroidal Anti-Inflammatory Drugs (NSAID): Selective COX-2 Inhibitors; Non-Selective NSAIDs
3) By Other Drug Classes: Opioids; Tricyclic Antidepressants (TCAs); Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=13950&type=smp
Which Areas Are Leading Regions in the Visceral Pain Market Expansion Across the Globe?
North America was the largest region in the visceral pain market in 2024. The regions covered in the visceral pain market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Strategic Trends Steering theVisceral Pain Market Direction?
Leading entities active in the visceral pain industry are introducing cutting-edge solutions such as NHE3 inhibitors to ensure trustworthy services to their clientele. NHE3 inhibitors are a type of drug that operate by suppressing the Sodium-Proton-Exchanger subtype 3 (NHE3) within the gastrointestinal tract. For example, in April 2022, Ardelyx, an American biopharmaceutical firm, brought their NHE3 inhibiting drug, IBSRELA, on the market. IBSRELA is a pioneering treatment for adults suffering from irritable bowel syndrome with constipation (IBS-C), functioning by blocking the Sodium-Hydrogen Exchanger 3 (NHE3) in the small intestine and colon. In addition, it has been proven to alleviate abdominal pain by lessening both visceral hypersensitivity and intestinal permeability, as demonstrated in animal studies.
View the full report here:
https://www.thebusinessresearchcompany.com/report/visceral-pain-global-market-report
How Is the Visceral Pain Market Conceptually Defined?
Visceral pain refers to the pain that originates from the internal organs, such as the stomach, bladder, uterus, or rectum. Visceral pain can be caused by various factors, including inflammation, menstrual cramps, swelling and stretching of the organs, blockage, decreased blood flow, and tumors, especially when concentrated in the pelvis or abdomen. It is commonly associated with additional symptoms such as nausea, perspiration, or an accelerated heartbeat.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13950
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model